利妥昔-话题@MedSci

#利妥昔#

179篇内容 | 3549人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1660437, encodeId=f5e5166043e30, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=Rheumatology (Oxford)：多大比例的类风湿关节炎患者使用利妥昔单抗4年以上？, objectType=article, longId=141358, objectId=88ef1413581a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=88ef1413581a, replyNumber=0, likeNumber=70, createdTime=2018-11-14, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=88ef1413581a, moduleTitle=Rheumatology (Oxford)：多大比例的类风湿关节炎患者使用利妥昔单抗4年以上？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=88ef1413581a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660454, encodeId=a2ae1660454e0, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=J Hematol Oncol：套细胞淋巴瘤自体造血干细胞移植后硼替佐米+利妥昔单抗疗效喜人, objectType=article, longId=155661, objectId=4497155661dc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4497155661dc, replyNumber=0, likeNumber=84, createdTime=2019-08-10, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4497155661dc, moduleTitle=J Hematol Oncol：套细胞淋巴瘤自体造血干细胞移植后硼替佐米+利妥昔单抗疗效喜人, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4497155661dc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660447, encodeId=a60e166044ed7, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=N Engl J Med:晚期滤泡性淋巴瘤：利妥昔单抗+来那度胺vs利妥昔单抗+化疗, objectType=article, longId=149892, objectId=952414989202, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=952414989202, replyNumber=0, likeNumber=66, createdTime=2018-11-28, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=952414989202, moduleTitle=N Engl J Med:晚期滤泡性淋巴瘤：利妥昔单抗+来那度胺vs利妥昔单抗+化疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=952414989202)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660432, encodeId=e8ef166043222, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=P53基因重排/突变的白血病非淋巴结套细胞淋巴瘤对利妥昔单抗/伊布替尼组合疗法高度敏感, objectType=article, longId=133937, objectId=40e013393ec7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=40e013393ec7, replyNumber=0, likeNumber=79, createdTime=2018-05-17, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=40e013393ec7, moduleTitle=P53基因重排/突变的白血病非淋巴结套细胞淋巴瘤对利妥昔单抗/伊布替尼组合疗法高度敏感, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=40e013393ec7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660434, encodeId=4f0916604344b, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=Ann Rheum Dis：利妥昔单抗的个体化定制与固定时间表方案维持ANCA相关性血管炎缓解的比较, objectType=article, longId=136554, objectId=b50513655472, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b50513655472, replyNumber=0, likeNumber=78, createdTime=2019-04-04, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b50513655472, moduleTitle=Ann Rheum Dis：利妥昔单抗的个体化定制与固定时间表方案维持ANCA相关性血管炎缓解的比较, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b50513655472)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660425, encodeId=668b16604251d, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=徐卫教授：Venetoclax联合利妥昔单抗——难治复发CLL治疗的新方向, objectType=article, longId=123144, objectId=efa61231449d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=efa61231449d, replyNumber=0, likeNumber=72, createdTime=2018-04-17, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=efa61231449d, moduleTitle=徐卫教授：Venetoclax联合利妥昔单抗——难治复发CLL治疗的新方向, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=efa61231449d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660449, encodeId=212a1660449ef, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=NEJM：Hu5F9-G4和利妥昔单抗联合阻断非霍奇金淋巴瘤中CD47的疗效评价, objectType=article, longId=152500, objectId=897a152500bf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=897a152500bf, replyNumber=0, likeNumber=62, createdTime=2019-08-06, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=897a152500bf, moduleTitle=NEJM：Hu5F9-G4和利妥昔单抗联合阻断非霍奇金淋巴瘤中CD47的疗效评价, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=897a152500bf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660422, encodeId=059e1660422e8, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=Blood：FOXP1表达可作为预测利妥昔单抗治疗滤泡性淋巴瘤预后的标志物。, objectType=article, longId=120773, objectId=59cb120e7346, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=59cb120e7346, replyNumber=0, likeNumber=66, createdTime=2018-04-12, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=59cb120e7346, moduleTitle=Blood：FOXP1表达可作为预测利妥昔单抗治疗滤泡性淋巴瘤预后的标志物。, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=59cb120e7346)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660420, encodeId=9da51660420ad, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=Am J Hematol：EPOCH联合利妥昔单抗治疗的淋巴瘤患者CNS复发率如何？, objectType=article, longId=119137, objectId=94bf11913e4a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=94bf11913e4a, replyNumber=0, likeNumber=102, createdTime=2018-02-10, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=94bf11913e4a, moduleTitle=Am J Hematol：EPOCH联合利妥昔单抗治疗的淋巴瘤患者CNS复发率如何？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=94bf11913e4a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660418, encodeId=03741660418eb, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=Arthritis Rheumatol：利妥昔单抗治疗成人发病的IgA血管炎（过敏性紫癜）, objectType=article, longId=116379, objectId=1adc1163e935, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1adc1163e935, replyNumber=0, likeNumber=105, createdTime=2018-05-21, rootId=0, userName=heli0118, userId=21015, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1adc1163e935, moduleTitle=Arthritis Rheumatol：利妥昔单抗治疗成人发病的IgA血管炎（过敏性紫癜）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1adc1163e935)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660426, encodeId=5ea016604268d, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=Lancet haemat：利妥昔单抗用于化疗诱导缓解的慢性淋巴细胞白血病老年患者的维持治疗的效果和安全性。, objectType=article, longId=124145, objectId=d43c12414522, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d43c12414522, replyNumber=0, likeNumber=79, createdTime=2018-09-02, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d43c12414522, moduleTitle=Lancet haemat：利妥昔单抗用于化疗诱导缓解的慢性淋巴细胞白血病老年患者的维持治疗的效果和安全性。, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d43c12414522)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660427, encodeId=13b6166042eb2, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=Ann Rheum Dis：利妥昔单抗对原发性干燥综合征患者唾液腺超声评分的影响, objectType=article, longId=124467, objectId=7d9912446e0f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7d9912446e0f, replyNumber=0, likeNumber=82, createdTime=2018-07-20, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7d9912446e0f, moduleTitle=Ann Rheum Dis：利妥昔单抗对原发性干燥综合征患者唾液腺超声评分的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7d9912446e0f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660439, encodeId=98181660439c1, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=Ann Rheum Dis：复方新诺明可以预防ANCA相关血管炎利妥昔单抗治疗后的严重感染, objectType=article, longId=141964, objectId=530f141964c5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=530f141964c5, replyNumber=0, likeNumber=81, createdTime=2018-11-29, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=530f141964c5, moduleTitle=Ann Rheum Dis：复方新诺明可以预防ANCA相关血管炎利妥昔单抗治疗后的严重感染, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=530f141964c5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660430, encodeId=898316604306b, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=Lancet Haematol：改善CLL老年患者生存期：利妥昔单抗维持治疗 vs 观察治疗, objectType=article, longId=130401, objectId=0ffc13040150, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0ffc13040150, replyNumber=0, likeNumber=75, createdTime=2018-07-02, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0ffc13040150, moduleTitle=Lancet Haematol：改善CLL老年患者生存期：利妥昔单抗维持治疗 vs 观察治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0ffc13040150)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660436, encodeId=7c1316604369e, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=NEJM：伊布替尼联合利妥昔单抗用于治疗瓦尔登斯特伦巨球蛋白血症, objectType=article, longId=140055, objectId=083e140055f2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=083e140055f2, replyNumber=0, likeNumber=65, createdTime=2018-11-20, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=083e140055f2, moduleTitle=NEJM：伊布替尼联合利妥昔单抗用于治疗瓦尔登斯特伦巨球蛋白血症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=083e140055f2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660419, encodeId=10ad166041994, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=复发/难治CLL/SLL患者中比较伊布替尼和利妥昔单抗：一项随机开放性Ⅲ期研究, objectType=article, longId=116543, objectId=2f6e116543b5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2f6e116543b5, replyNumber=0, likeNumber=55, createdTime=2018-09-11, rootId=0, userName=heli0118, userId=21015, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2f6e116543b5, moduleTitle=复发/难治CLL/SLL患者中比较伊布替尼和利妥昔单抗：一项随机开放性Ⅲ期研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2f6e116543b5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660428, encodeId=15291660428de, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=JAMA Neurol：利妥昔单抗、富马酸二甲酯、芬戈莫德、那他珠单抗以及其他症状缓解治疗药物对复发缓解多发性硬化症的治疗效果比较研究, objectType=article, longId=126027, objectId=39af12602e4e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=39af12602e4e, replyNumber=0, likeNumber=51, createdTime=2018-09-24, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=39af12602e4e, moduleTitle=JAMA Neurol：利妥昔单抗、富马酸二甲酯、芬戈莫德、那他珠单抗以及其他症状缓解治疗药物对复发缓解多发性硬化症的治疗效果比较研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=39af12602e4e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660421, encodeId=7c2a1660421f8, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=【ASH 2017】一线免疫化疗后序贯利妥昔单抗维持治疗套细胞淋巴瘤的长期随访结果, objectType=article, longId=120688, objectId=a371120688d3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a371120688d3, replyNumber=0, likeNumber=84, createdTime=2018-07-14, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a371120688d3, moduleTitle=【ASH 2017】一线免疫化疗后序贯利妥昔单抗维持治疗套细胞淋巴瘤的长期随访结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a371120688d3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660413, encodeId=20cb166041339, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=Leuk Lymphoma：利妥昔单抗存在不良反应新模式识别高风险患者, objectType=article, longId=108884, objectId=bc961088844e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bc961088844e, replyNumber=0, likeNumber=66, createdTime=2018-03-04, rootId=0, userName=heli0118, userId=21015, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bc961088844e, moduleTitle=Leuk Lymphoma：利妥昔单抗存在不良反应新模式识别高风险患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bc961088844e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660429, encodeId=e45916604298f, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=Lancet haemat：R-CHOP、放疗、利妥昔单抗维持的序贯疗法治疗晚期滤泡性淋巴瘤的效果和安全性, objectType=article, longId=127695, objectId=d57d12e6952c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d57d12e6952c, replyNumber=0, likeNumber=75, createdTime=2018-09-03, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d57d12e6952c, moduleTitle=Lancet haemat：R-CHOP、放疗、利妥昔单抗维持的序贯疗法治疗晚期滤泡性淋巴瘤的效果和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d57d12e6952c)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

利妥昔

2020-05-29

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

Rheumatology (Oxford)：多大比例的类风湿关节炎患者使用利妥昔单抗4年以上？

2018-11-14

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

J Hematol Oncol：套细胞淋巴瘤自体造血干细胞移植后硼替佐米+利妥昔单抗疗效喜人

2019-08-10

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

N Engl J Med:晚期滤泡性淋巴瘤：利妥昔单抗+来那度胺vs利妥昔单抗+化疗

2018-11-28

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

P53基因重排/突变的白血病非淋巴结套细胞淋巴瘤对利妥昔单抗/伊布替尼组合疗法高度敏感

2018-05-17

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

Ann Rheum Dis：利妥昔单抗的个体化定制与固定时间表方案维持ANCA相关性血管炎缓解的比较

2019-04-04

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

徐卫教授：Venetoclax联合利妥昔单抗——难治复发CLL治疗的新方向

2018-04-17

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

NEJM：Hu5F9-G4和利妥昔单抗联合阻断非霍奇金淋巴瘤中CD47的疗效评价

2019-08-06

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

Blood：FOXP1表达可作为预测利妥昔单抗治疗滤泡性淋巴瘤预后的标志物。

2018-04-12

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

Am J Hematol：EPOCH联合利妥昔单抗治疗的淋巴瘤患者CNS复发率如何？

2018-02-10

heli0118 (审核中...)

前往app查看评论内容

#利妥昔#

Arthritis Rheumatol：利妥昔单抗治疗成人发病的IgA血管炎（过敏性紫癜）

2018-05-21

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

Lancet haemat：利妥昔单抗用于化疗诱导缓解的慢性淋巴细胞白血病老年患者的维持治疗的效果和安全性。

2018-09-02

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

Ann Rheum Dis：利妥昔单抗对原发性干燥综合征患者唾液腺超声评分的影响

2018-07-20

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

Ann Rheum Dis：复方新诺明可以预防ANCA相关血管炎利妥昔单抗治疗后的严重感染

2018-11-29

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

Lancet Haematol：改善CLL老年患者生存期：利妥昔单抗维持治疗 vs 观察治疗

2018-07-02

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

NEJM：伊布替尼联合利妥昔单抗用于治疗瓦尔登斯特伦巨球蛋白血症

2018-11-20

heli0118 (审核中...)

前往app查看评论内容

#利妥昔#

复发/难治CLL/SLL患者中比较伊布替尼和利妥昔单抗：一项随机开放性Ⅲ期研究

2018-09-11

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

JAMA Neurol：利妥昔单抗、富马酸二甲酯、芬戈莫德、那他珠单抗以及其他症状缓解治疗药物对复发缓解多发性硬化症的治疗效果比较研究

2018-09-24

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

【ASH 2017】一线免疫化疗后序贯利妥昔单抗维持治疗套细胞淋巴瘤的长期随访结果

2018-07-14

heli0118 (审核中...)

前往app查看评论内容

#利妥昔#

Leuk Lymphoma：利妥昔单抗存在不良反应新模式识别高风险患者

2018-03-04

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

Lancet haemat：R-CHOP、放疗、利妥昔单抗维持的序贯疗法治疗晚期滤泡性淋巴瘤的效果和安全性

2018-09-03

科室
- - 订阅+
  - 更多科室
工具
服务